Screener
LABU vs CURE
Direxion Daily S&P Biotech Bull 3X Shares vs Direxion Daily Healthcare Bull 3X Shares
Key differences
- LABU is significantly larger than CURE — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, LABU has delivered higher annualized returns.
Side-by-side comparison
| LABU | CURE | |
|---|---|---|
| Annual cost (TER) | 0.96% | 0.94% |
| Fund size (AUM) | $528M | $138M |
| Since | 2015 | 2011 |
| Dividend yield | 0.69% | 1.33% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | leveraged | leveraged |
| CAGR 1Y | +246.3% | +31.7% |
| CAGR 3Y | +10.2% | +0.8% |
| CAGR 5Y | -32.0% | +0.7% |
| Sharpe 3Y | 0.48 | 0.14 |
| Volatility 1Y | 75.02% | 42.92% |
| Max drawdown | -98.96% | -69.19% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to LABU and CURE
Explore further